Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D008297:Male; D008937:Mitomycins / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D013311:Streptozocin / Q000008:administration & dosage / Q000031:analogs & derivatives
D000970:Antineoplastic Agents; D008937:Mitomycins; C007028:chlorozotocin; D013311:Streptozocin; D004317:Doxorubicin; D005472:Fluorouracil